ADDED
These forward-looking statements include, among other things, statements regarding our financial and operating performance; acquisitions; clinical trials; business plans and product performance; new and anticipated product approvals and launches; intellectual property; regulations and accounting pronouncements; legal proceedings; tax matters and regulations; and macroeconomic and geopolitical conditions.
Risk Factors contained in this Annual Report, which we may update in Part II, Item 1A.
Risk Factors in Quarterly Reports on Form 10-Q that we have filed or will file hereafter.
This includes taking actions to drive innovative care, contribute to the communities where we live and work, protect the environment, invest in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly.
Refer to Corporate Responsibility below for additional information regarding measures we are undertaking.
Product Offerings Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
In the fourth quarter of 2025, an organizational change combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business.
MedSurg Endoscopy Our Endoscopy business unit develops and manufactures minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions and for supporting weight loss in patients with obesity.
Urology Our Urology business unit develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and male incontinence, over active bladder and pelvic floor disorders.
Our product offerings include our WaveWriter Alpha Spinal Cord Stimulator (SCS) System, designed to provide improved pain relief to a wide range of patients who suffer from chronic pain, our Intracept Intraosseous Nerve Ablation System, the only U.S.
REMOVED
This includes taking actions to advance diversity and inclusion, including through financial support of equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly.
Refer to discussion of Community Outreach and Corporate Responsibility below for additional information regarding measures we are undertaking.
MedSurg Endoscopy Our Endoscopy business unit develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies.
Our product offerings include the following: Resolution 360 Clips, Resolution 360 ULTRA Clips and MANTIS Clips, hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures, WallFlex Biliary Stent Systems, used for relieving biliary obstructions by providing bile drainage in both malignant and benign strictures, 3 AXIOS Stents and Electrocautery Enhanced Delivery Systems, the first, and currently only stent systems in the U.S.
indicated for endoscopic drainage of pancreatic pseudocysts and used to facilitate endoscopic drainage of the gallbladder for patients with acute cholecystitis, SpyGlass DS II Direct Visualization Systems and SpyGlass Discover Digital Catheters, the first single-use scopes to enable physicians to take a single-stage approach to diagnostic and therapeutic procedures in the pancreaticobiliary system, including treating patients with bile duct stones, EXALT Model D Single-Use Duodenoscopes for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures, the first U.S.
Food and Drug Administration (FDA)-cleared single-use (disposable) duodenoscopes on the market, our endoluminal surgery portfolio, including our OverStitch Endoscopic Suturing System, used to close gastrointestinal defects and our endobariatric portfolio, including our Orbera Intragastric Balloon System used to aid in weight loss for patients suffering from obesity and our infection prevention portfolio, designed to minimize the risk of infection transmission and improve operational efficiencies by streamlining manual cleaning or eliminating the need for cleaning and tracking.
Urology Our Urology business unit develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence.
In the fourth quarter of 2024, we completed the acquisition of Axonics, Inc.
(Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.
The Axonics product portfolio includes the Axonics R20 and Axonics F15 Systems used to deliver sacral neuromodulation (SNM) therapy for the treatment of over-active bladder and fecal incontinence.